Ultragenyx Pharmaceutical Inc. (RARE) NASDAQ
26.12
-0.01(-0.04%)
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
26.12
-0.01(-0.04%)
Currency In USD
| Previous Close | 26.13 |
| Open | 26.23 |
| Day High | 26.67 |
| Day Low | 25.93 |
| 52-Week High | 42.37 |
| 52-Week Low | 18.29 |
| Volume | 1.56M |
| Average Volume | 2.05M |
| Market Cap | 2.57B |
| PE | -4.28 |
| EPS | -6.1 |
| Moving Average 50 Days | 22.83 |
| Moving Average 200 Days | 27.69 |
| Change | -0.01 |
Ultragenyx Announces U.S. FDA Acceptance and Priority Review of the Biologics License Application (BLA) for DTX401 AAV Gene Therapy for Glycogen Storage Disease Type Ia (GSDIa)
GlobeNewswire Inc.
Feb 23, 2026 1:30 PM GMT
PDUFA action date set for August 23, 2026 If approved, DTX401 will be the first treatment to address the underlying cause of GDSIa NOVATO, Calif., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) today announced the U
Ultragenyx to Host Conference Call for Fourth Quarter and Full-Year 2025 Financial Results and Corporate Update
GlobeNewswire Inc.
Feb 05, 2026 9:05 PM GMT
NOVATO, Calif., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel products for serious rare and ultra-rare genetic diseases, today
Ultragenyx Announces Positive Longer-Term Data Demonstrating Treatment with UX111 Gene Therapy Results in Sustained, Significant Reductions in CSF-HS and Continued Meaningful Improvements in Clinical Function Across Multiple Developmental Domains in Children with Sanfilippo Syndrome (MPS IIIA)
GlobeNewswire Inc.
Feb 03, 2026 1:00 PM GMT
Data represents up to 8.5 years of follow-up and are consistent across age, dose, and genotype BLA resubmitted to U.S. FDA in January 2026; Company expects up to six-month review period per FDA guidelines NOVATO, Calif., Feb. 03, 2026 (GLOBE NEWSW